Lucy Meunier
Overview
Explore the profile of Lucy Meunier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
354
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hountondji L, Meunier L
Aliment Pharmacol Ther
. 2024 Oct;
60(11-12):1623-1624.
PMID: 39400950
No abstract available.
2.
Hountondji L, Faure S, Palassin P, Viel P, Dupuy M, Larrey D, et al.
Aliment Pharmacol Ther
. 2024 Sep;
60(11-12):1561-1572.
PMID: 39315730
Background And Aims: While immune checkpoint inhibitors (ICIs) are revolutionising cancer therapy, checkpoint inhibitor-induced liver injury is a significant immune-related side effect of this immunotherapy. This study focuses on the...
3.
Larrey D, Delire B, Meunier L, Zahhaf A, De Martin E, Horsmans Y
Liver Int
. 2024 Sep;
44(12):3121-3137.
PMID: 39248281
Gene therapy is being successfully developed for the treatment of several genetic disorders. Various methods of gene transfer have been developed to enable the production of the deficient enzyme or...
4.
Meunier L, De Martin E, Delire B, Jacot W, Guiu S, Zahhaf A, et al.
JHEP Rep
. 2024 Jul;
6(7):101098.
PMID: 38961854
Background & Aims: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are the cornerstone of systemic therapy for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer. In the various therapeutic studies with...
5.
Kocheise L, Piseddu I, Vonderlin J, Tjwa E, Buescher G, Meunier L, et al.
Front Immunol
. 2024 Feb;
15:1369747.
PMID: 38327519
[This corrects the article DOI: 10.3389/fimmu.2023.1326078.].
6.
Kocheise L, Piseddu I, Vonderlin J, Tjwa E, Buescher G, Meunier L, et al.
Front Immunol
. 2024 Jan;
14:1326078.
PMID: 38268921
Introduction: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many malignancies in recent years. However, immune-related adverse events (irAE) are a frequent concern in clinical practice. The safety profile...
7.
8.
Meunier L, Hountondji L, Jantzem H, Faillie J, Maria A, Palassin P
Clin Gastroenterol Hepatol
. 2023 Dec;
22(7):1542-1545.e4.
PMID: 38110061
Immune checkpoint inhibitors (ICIs) are remarkable anticancer therapies that have revolutionized the oncological prognosis of many cancers. The considerable efficacy of ICIs is associated with the onset of more- or...
9.
Daniel J, Dumortier J, Del Bello A, Gamon L, Molinari N, Faure S, et al.
JHEP Rep
. 2023 Sep;
5(10):100832.
PMID: 37681206
Background & Aims: Liver transplantation (LT) is a last resort treatment for patients at high risk of mortality from end-stage liver disease. Over the past years, alcohol-associated liver disease has...
10.
Renault T, Meunier L, Monet C
Clin Res Hepatol Gastroenterol
. 2023 Sep;
47(8):102203.
PMID: 37660741
We report the case of a 64-year-old man admitted to intensive care unit for liver failure secondary to immune-mediated hepatitis. This patient suffered from a progressing laryngeal squamous cell carcinoma....